The EZH2 polycomb transcriptional repressor--a marker or mover of metastatic prostate cancer?
Review
Overview
abstract
The recent finding of overexpression of the polycomb group transcriptional repressor EZH2 in prostate cancer raises the possibility that transcriptional regulation at the chromatin level may play a role in the development of the metastatic phenotype and suggests new avenues of exploration with respect to patient stratification and therapeutics.
